Stalicla
Biologically driven precision medicine for neurodevelopmental disorders
Problem
Patient diagnosis and drug development for Autism Syndrome Disorder and other Neurodevelopmental Disorders have relied on behaviorally based disease classifications, which do not correlate with biological status and fail to acknowledge patient diversity, contributing to high rates of clinical failure.
Investment Rationale
Stalicla is targeting one of the largest underserve needs in medicine, NDDs. Playing in a usually capital restrictive field, Lynn-Allison Durham, Stalicla founder, presented an efficient strategy that reduces common risks associated with biotech firms through drug repositioning, patient segmentation, and early revenue potential of the proprietary systems biology platform (DEPI).
Her knowledge of the field combined with her drive and early traction enabled us to build the necessary conviction to support Lynn at an early stage.
